At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Cabozantinib for Breast Cancer. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This research study is studying a combination of drugs as a possible treatment for metastatic triple-negative breast cancer. The drugs involved in this study are: * Cabozantinib (XL184) * Nivolumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Exelixis
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionAug 2019
TodayJul 2026
First PostedOct 20, 2017
Enrollment StartNov 30, 2017
Primary CompletionAug 30, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.7 years ago
Interventions
Nivolumabdrug
Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
Cabozantinibdrug
Cabozantinib may help to shrink or stabilize breast cancer